<SUBMISSION>
<ACCESSION-NUMBER>0001079973-04-000516
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>2
<PERIOD>20041001
<ITEMS>5.02
<ITEMS>9.01
<FILING-DATE>20041004
<DATE-OF-FILING-DATE-CHANGE>20041004
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>ASPENBIO INC
<CIK>0001167419
<ASSIGNED-SIC>2835
<IRS-NUMBER>841553387
<STATE-OF-INCORPORATION>CO
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-50019
<FILM-NUMBER>041062392
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>1585 S. PERRY STREET
<STREET2>ASPENBIO INC.
<CITY>CASTLE ROCK
<STATE>CO
<ZIP>80104
<PHONE>(303) 794-2000
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>1585 S. PERRY STREET
<STREET2>ASPENBIO INC.
<CITY>CASTLE ROCK
<STATE>CO
<ZIP>80104
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>aspenbio8k_welch100404.txt
<DESCRIPTION>CURRENT EVENT REPORT
<TEXT>
                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
                       Pursuant to Section 13 OR 15(d) of
                       The Securities Exchange Act of 1934

        Date of Report (Date of earliest event reported) October 1, 2004


                                  AspenBio, Inc
              ----------------------------------------------------
             (Exact name of registrant as specified in its charter)


         Colorado                         0-50019                84-1553387
         --------                         -------                ----------
(State or other jurisdiction            (Commission             (IRS Employer
       of incorporation)                File Number)         Identification No.)



         1585 South Perry Street, Castle Rock, CO                      80104
         -----------------------------------------                     -----
          (Address of principal executive offices)                  (Zip Code)


        Registrant's telephone number, including area code (303) 794-2000



Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[  ] Written communications pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))




<PAGE>




Item 5.02(d) - Appointment of Additional Director.
               -----------------------------------

     On October 1, 2004, the Board of Directors of AspenBio, Inc. approved an
expansion of the number of Board members to five, and appointed David Welch to
fill the vacancy on the Board created by the expansion. Mr. Welch was granted
options to purchase 100,000 shares of the Company's common stock, exercisable at
$0.76 per shares, which grant is consistent with other directors' appointments
to the Company's Board. The Company's Nominating and Corporate Governance
Committee recommended that Mr. Welch be appointed to the Board. Mr. Welch was
also appointed as Chair of the Audit Committee and as a member of the
Compensation, Nominating and Corporate Governance Committees.


Item 9.01 - Financial Statements and Exhibits.
            ----------------------------------

 (c) Exhibits.

     99.1 Press Release dated October 4, 2004.




                                   SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                                        AspenBio, Inc
                                                         (Registrant)

Date October 4, 2004                              /s/ Jeffrey G. McGonegal
                                                  ------------------------
                                                 Name: Jeffrey G. McGonegal
                                               Title: Chief Financial Officer




<PAGE>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>aspenbio8kwelch_ex991.txt
<DESCRIPTION>PRESS RELEASE DATED 10/04/2004
<TEXT>
                                                                   Exhibit 99.1


For Immediate Release                               For more information contact
                                                        Roger Hurst 303-794-2000


             AspenBio Appoints David Welch to the Board of Directors

Castle Rock, CO, October 4, 2004 - AspenBio, Inc. (OTCBB: APNB) announced today
that David Welch has been appointed to the Board of Directors. Mr. Welch has
also been elected as Chairman of the Company's Audit Committee and will serve as
a member of the Compensation, Nominating and Corporate Governance committees.
Mr. Welch brings significant hands-on experience in dealing with issues facing
small public companies.

David E. Welch, age 57, has served as Vice President and Chief Financial Officer
of American Millennium Corporation, Inc., a public company located in Golden,
Colorado, since April 2004. He also is a self-employed financial consultant.
From July 1999 to June 2002 Mr. Welch served as Chief Financial Officer,
Secretary and Treasurer of Active Link Communications, Inc., another publicly
traded company. During 1998 he served as Chief Information Officer for Language
Management International, Inc., a multinational translation firm located in
Denver, Colorado. From 1996 to 1997, he was Director of Information Systems for
Mircromedex, Inc., an electronic publishing firm, located in Denver, Colorado.
Mr. Welch also serves on the Boards of Directors of Advanced Nutraceuticals,
Inc., and Communication Intelligence Corporation, both publicly traded
companies.

"We believe that Mr. Welch's addition to the Company's Board will bring
significant expertise to assist AspenBio with the complex reporting and
operational requirements facing public companies in today's environment" stated
Roger Hurst, President of AspenBio, Inc.


This news release includes "forward looking statements" of AspenBio, Inc.
("APNB") as defined by the Securities and Exchange Commission (the "SEC"). All
statements, other than statements of historical fact, included in the press
release that address activities, events or developments that APNB believes or
anticipates will or may occur in the future are forward-looking statements.
These statements are based on certain assumptions made based on experience,
expected future developments and other factors APNB believes are appropriate in
the circumstances. Such statements are subject to a number of assumptions, risks
and uncertainties, many of which are beyond the control of APNB. Investors are
cautioned that any such statements are not guarantees of future performance.
Actual results or developments may differ materially from those projected in the
forward-looking statements as a result of many factors, including development of
new products, obtaining additional funding, adverse changes in market
conditions, fluctuations in sales volumes, and problems in collecting
receivables. Furthermore, APNB does not intend (and is not obligated) to update
publicly any forward-looking statements. The contents of this news release
should be considered in conjunction with the warnings and cautionary statements
contained in APNB's recent filings with the SEC.



</TEXT>
</DOCUMENT>
</SUBMISSION>
